Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib Combinations in Relapsed/Refractory AML
NCT06001788Phase 1Recruiting
- Sponsor
- Kura Oncology
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of ziftomenib in acute myeloid leukemia (AML) (2 arms), sponsored by Kura Oncology. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events. Started Feb 2024; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06001788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001788.